The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
Nathan Fowler(Repligen (United States)), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Karl Eckert(AbbVie (United States)), Melannie Co(AbbVie (United States)), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Peter Martin(Northwestern University), Ranjana H. Advani(Stanford Medicine), R. Eric Davis(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Jutta K. Neuenburg(Gladstone Institutes), Mark Knapp, Sumeet Bhatia, Sven de Vos(University of California, Los Angeles), Jerry Ping(AbbVie (United States)), Robert Chen(AstraZeneca (United States)), Ian W. Flinn(Tennessee Oncology), Raul Mena, Darrin M. Beaupre(Pharmacyclics (United States))
Cited by 28
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k